ஆநிஶ் பட்நகர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Soleno Therapeutics Participates in Prader-Willi Syndrome (PWS) DCCR Town Hall April 14, 2021 20:40 ET | Source: Soleno Therapeutics Soleno Therapeutics Redwood City, UNITED STATES REDWOOD CITY, Calif., April 14, 2021 (GLOBE NEWSWIRE) Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, participated in a Prader-Willi Syndrome (PWS) DCCR Town Hall on Wednesday, April 14, 2021. The event featured speakers from the PWS community who discussed the challenges of living with PWS, as well as patient and caregiver perspectives on DCCR treatment. Dr. Bhatnagar’s remarks highlighted the unmet medical needs facing PWS patients, the Company’s ongoing commitment to obtaining regulatory approval for DCCR and an outline of the necessary steps to obtain reg

United statesManish bhatnagarBrian ritchieSoleno therapeutics incPrader willi syndrome association united statesLifesci advisorsFoundation for prader willi researchDrug administrationSecurities exchangeChief executive officerPrader willi syndromePrader willi researchPrader willi syndrome associationOrphan drug designationFast track designationDiazoxide choline